1 February 2022
The BioEscalator is sponsoring a prize for the Biohackaton 2022, where teams created during the Oxford Catalyse 2022 programme will pitch their final business plans to a panel of judges.
1 February 2022
In December 2021, the BioEscalator opened a brand-new 137m2 laboratory, providing much-needed additional incubator space for Oxford-based start-ups.
25 January 2022
The research collaboration will investigate TPOXX® (tecovirimat) in combination with Bioarchitech’s proprietary vaccinia-based immunotherapy platform in preclinical studies.
19 January 2022
Keating brings strong experience as a life science executive and Board member.
3 January 2022
Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
14 December 2021
The two companies share the same goals, to improve the lives of those dealing with liver disease.
PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle to Senior Vice President, Strategy & Operations
7 December 2021
Dr Bracegirdle will lead the expanded PepGen Strategy and Operations team. Isami J. Salcedo, experienced biotechnology operations and programme management professional, joins as Vice President of Program Management.
22 November 2021
Helping people get the answers they need to make more informed decisions across the cancer continuum.
Gene Linked to Doubling the Risk of Death due to COVID-19 Identified Using Technology Exclusively Licensed to Nucleome Therapeutics
5 November 2021
The technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome’s platform in the discovery of genetic targets for innovative precision medicine development.
4 November 2021
KQ Labs is a five-month accelerator programme for exciting early-stage startups using data as a core part of their business model to improve human health, run by the Francis Crick Institute and funded by LifeArc.
28 October 2021
The new appointment represents a continued expansion of PepGen’s leadership team in Boston following successful $112.5 million Series B financing.
22 October 2021
Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
1 September 2021
The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.
31 August 2021
Heidi Henson will join PepGen’s Board of Directors. The company also announced the promotion of Jane Larkindale, PhD, to Vice President of Clinical Science.
18 August 2021
Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of £1.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.
PepGen Announces Closing of $112.5M Crossover Financing to Advance Transformative Therapies for Neuromuscular Diseases
5 August 2021
Proceeds to support expansion and advancement of PepGen’s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
23 July 2021
After a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
25 June 2021
MediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
18 June 2021
The funding will be used to advance the development of Ochre Bio’s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.
11 June 2021
Alchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.